CEL-SCI Corporation (CEL-SCI) is a research and development company focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The Company is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. Its investigational immunotherapy is Multikine (Leukocyte Interleukin, Injection). The Company’s Multikine, is being studied in a pivotal global Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a Cooperative Research and Development Agreement (CRADA) in HIV/HPV co-infected men and women with peri-anal warts. The Company also owns and is developing a pre-clinical technology called Ligand Epitope Antigen Presentation System (LEAPS).